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Purpose of the study
Atazanavir (ATV)-based regimens have demonstrated
efficacy and safety in both ARV-naïve and -experienced
patients. However, few reports have assessed effectiveness
beyond 2 years. The aim of this study was to describe the
long-term outcomes of ATV/r containing regimens in
ARV-experienced patients in a clinical setting.
Methods
Non-comparative, retrospective, observational study which
collected data from 3 European databases (France-
DatAids, Germany-KompNet, Sweden-InfCare). Clinical
data for ARV-experienced adult patients who started an
ATV/r-based regimen between October, 2004 and March,
2007 were extracted every 6-months (maximum follow-up
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Figure 1 Time to virologic failure (two consecutive HIV-1 RNA ≥ 50 c/mL or one HIV-1 RNA ≥ 50 c/mL followed by discontinuation)
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any medium, provided the original work is properly cited.5 years). Primary endpoint was the proportion of patients
remaining on ATV treatment by baseline HIV-1 RNA (<
500 or ≥ 500 c/mL). Secondary endpoints included virolo-
gic response and reason for discontinuation. The duration
of treatment and time to virologic failure were analyzed
using the Kaplan-Meier method.
Summary of results
Data for 1294 ARV-experienced patients (prior ARV
exposure: mean, 5.70 years) were analyzed. Patients
were predominantly male (74%); median age 43 years
(min, max: 18, 85); 75% had prior exposure to PIs
(mean: 3.5 years). At baseline (BL), 56% of patients had
HIV-1 RNA < 500 c/mL and 37% had < 50 c/mL. The
estimated proportion of patients remaining on ATV
during the follow-up period was 52% (median duration
of treatment: 3.7 years); 54% for patients with BL HIV-1
RNA < 500 c/mL and 50% for those with BL HIV-1
RNA > 500 c/mL. The estimated probability of disconti-
nuation was 21% during the first year and decreased at
each subsequent 1-year treatment interval. Time to viro-
logic failure is presented in Figure 1.
The most frequent reasons for discontinuation were
“unknown” (32%), adverse events (25%), patient with-
drew consent (13%) and lack of efficacy (11%). Hyperbi-
lirubinemia was reported as reason for discontinuation
in 12 patients. No unexpected changes in metabolic
parameters were observed and renal AEs were reported
rarely (1.9/100 patient-years).
Conclusions
In real life setting, ATV/r-based regimen demonstrated
sustained virological efficacy in an ARV-experienced
population including patients with previous virological
failure. After long-term treatment a high proportion of
patients remained on an ATV regimen and no unex-
pected AEs were observed.
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